aTyr PharmaATYR +1.98%14 PS Ratio is 283.20 as of Jun. 29, 2026, which is 743% above its 10-year median of 33.60. GuruFocus rates ATYR with a GF Score™ of 14/100 and a GF Value™ of $0.46 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 935 Biotechnology companies, aTyr Pharma ranks worse than 91.02% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, aTyr Pharma's share price is $0.5664.
aTyr Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Hence, aTyr Pharma's PS Ratio for today is 283.20.
The historical rank and industry rank for aTyr Pharma's PS Ratio or its related term are showing as below:
ATYR'
s PS Ratio Range Over the Past 10 Years
Min: 2.19 Med: 33.6 Max: 1507.5
Current: 283.22
During the past 13 years, aTyr Pharma's highest PS Ratio was 1507.50. The lowest was 2.19. And the median was 33.60.
ATYR's PS Ratio is ranked worse than 91.02% of 935
companies
in the Biotechnology industry
Industry Median: 9.29
vs ATYR: 283.22
aTyr Pharma Inc revenue per share has been in decline over the past 3 years.
During the past 3 years, the average Revenue per Share Growth Rate was -82.40% per year.
During the past 13 years, aTyr Pharma's highest 3-Year average Revenue per Share Growth Rate was 42.60% per year. The lowest was -82.40% per year. And the median was -81.70% per year.
Back to Basics: PS Ratio
aTyr Pharma (NAS:ATYR) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
aTyr Pharma PS Ratio Related Terms
aTyr Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for aTyr Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, aTyr Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
aTyr Pharma's Share Price of today is $0.5664. aTyr Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
aTyr Pharma (ATYR) has a PS Ratio of 283.20 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on aTyr Pharma and its competitors. This is 743% above median its historical median of 33.60. Over the past decade, aTyr Pharma's PS Ratio has ranged from 2.19 to 1,507.50. According to the industry distribution chart, aTyr Pharma ranks #851 out of 935 companies in the Biotechnology industry, placing it in the top 91%.
Is aTyr Pharma's PS Ratio too high?
aTyr Pharma's current PS Ratio of 283.20 is 743% above median its 10-year median of 33.60. Over the past 10 years, this metric has ranged from a low of 2.19 to a high of 1,507.50. The Biotechnology industry median PS Ratio is 9.29. aTyr Pharma's value of 283.20 is 2948.4% above this industry median. Based on the distribution chart, aTyr Pharma ranks #851 out of 935 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's PS Ratio compare to DWTX and CNTX?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #851 out of 935 companies for PS Ratio. This places aTyr Pharma in the lower half of its industry. The industry median PS Ratio is 9.29. aTyr Pharma's value of 283.20 is 2948.4% above this benchmark. Historically, aTyr Pharma's own PS Ratio has ranged from 2.19 to 1,507.50 over the past decade. While the company's 10-year median is 33.60 vs. the industry median of 9.29, aTyr Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.29, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. aTyr Pharma's current PS Ratio of 283.20 is 2948.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on aTyr Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aTyr Pharma's current PS Ratio is 283.20, which is 743% above median its own 10-year median of 33.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.46, compared to a current price of $0.57 — trading 23.1% above its estimated fair value. The current PS Ratio is 283.20, which is 743% above median its 10-year median of 33.60 and 2948.4% above the Biotechnology industry median of 9.29. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current PS Ratio is 283.20 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aTyr Pharma (ATYR) Overvalued in 2026?
Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued.
The current stock price of $0.57 is trading 23.1% above its estimated GF Value™ of $0.46.
GuruFocus considers aTyr Pharma to be Modestly Overvalued.
Key valuation signals for ATYR:
PS Ratio: 283.20 (743% above median its 10-year median of 33.60)
GF Value™: $0.46 vs. price of $0.57 (23.1% above fair value)
Industry Position: 2948.4% above the Biotechnology median (#851 of 935)
No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score
Get the complete analysis for ATYR
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATYR has been successfully added to your 
